Review of fluconazole treatment and prophylaxis for invasive candidiasis in neonates.

Review of fluconazole treatment and prophylaxis for invasive candidiasis in neonates.

Hornik CD; Bondi DS; Greene NM; Cober MP; John B

Journal Of Pediatric Pharmacology & Therapeutics

2021

2021-02

Invasive candidiasis accounts for approximately 10% of nosocomial infections in preterm infants, with an incidence of 1% to 4% among neonatal intensive care unit (NICU) admissions and a mortality as high as 20% to 30%. These outcomes warrant improved treatment and prevention strategies for infants at highest risk. The Infectious Diseases Society of America provides guidelines on antifungal medications for the prophylaxis and treatment of candidiasis in NICUs; however, there are still variations in practice on the use of fluconazole for prophylaxis and treatment of invasive candidiasis. This review provides specific information regarding fluconazole activity, pharmacokinetics, and a literature evaluation of dosing strategies and comparisons to other treatments in the neonatal population. [ABSTRACT FROM AUTHOR]

amphotericin B; antifungal agents; Candida; candidiasis; DENTAL prophylaxis; fluconazole; FLUCONAZOLE; INVASIVE candidiasis; NEONATAL intensive care units; newborn; pharmacokinetics; PHARMACOKINETICS; PREMATURE infants

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

journalArticle

115-122

2

26

15516776

NEOMED College of Medicine

Department of Pharmacy Practice

April 2021 List